For the quarter ended March 2025, EyePoint Pharmaceuticals (EYPT) reported revenue of $24.45 million, up 109.4% over the same period last year. EPS came in at -$0.65, compared to -$0.55 in the year-ago quarter.
The reported revenue represents a surprise of +345.17% over the Zacks Consensus Estimate of $5.49 million. With the consensus EPS estimate being -$0.65, the company has not delivered EPS surprise.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how EyePoint Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Royalty income: $12.69 million versus the three-analyst average estimate of $0.33 million.
- Revenues- Product sales, net: $0.72 million versus the two-analyst average estimate of $0.85 million.
- Revenues- License and collaboration agreements: $11.05 million compared to the $6.90 million average estimate based on two analysts.
View all Key Company Metrics for EyePoint Pharmaceuticals here>>>
Shares of EyePoint Pharmaceuticals have returned +51.3% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
EYEPOINT PHARMACEUTICALS, INC. (EYPT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
